Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine for prevention of SIRS after retrograde endorenal surgery
IRCT20190624043991N40Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of fluoxetine in Systemic Inflammatory Response Syndrome (SIRS) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Systemic inflammatory response syndrome. Started Sep 2026; status: recruiting.
02
Drugs
fluoxetine
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on IRCT20190624043991N40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190624043991N40.